| Trial ID: | L1724 |
| Source ID: | NCT03381859
|
| Associated Drug: |
Elbasvir/Grazoprevir 50 Mg-100 Mg Oral Tablet [Zepatier]
|
| Title: |
Clinical Trial to eLiminate HCV-infection in Treatment-naïve, Renally Impaired EgyptiAn Patients on Renal Dialysis, With Chronic Hepatitis C Genotype 4
|
| Acronym: |
CLEAR-C4
|
| Status: |
WITHDRAWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Hepatitis C Virus Infection, Response to Therapy of
|
| Interventions: |
DRUG: Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER]
|
| Outcome Measures: |
Primary: SVR12, absence of HCV plasma RNA 12 weeks after end of treatment, 24 weeks from treatment initiation date |
|
| Sponsor/Collaborators: |
Sponsor: University of Maryland, Baltimore | Collaborators: Merck Sharp & Dohme LLC|Cairo University
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
0
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2019-12-01
|
| Completion Date: |
2020-06-01
|
| Results First Posted: |
|
| Last Update Posted: |
2020-04-20
|
| Locations: |
Kasr Alainy Hospital, Cairo, Almanial, Egypt
|
| URL: |
https://clinicaltrials.gov/show/NCT03381859
|
